Next Article in Journal
Environmental Stresses Induce Misfolded Protein Aggregation in Plant Cells in a Microtubule-Dependent Manner
Next Article in Special Issue
LILRA3 Is Associated with Benign Prostatic Hyperplasia Risk in a Chinese Population
Previous Article in Journal
Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer
Previous Article in Special Issue
Alteration of Podocyte Protein Expression and Localization in the Early Stage of Various Hemodynamic Conditions
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2013, 14(4), 7757-7770; doi:10.3390/ijms14047757

Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer

The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC V6H 3Z6, Canada
Departments of Experimental Therapeutics, Vancouver, BC V5Z 1L3, Canada
Departments of Medical Oncology, BC Cancer Agency, Vancouver, BC V5Z 4E6, Canada
Departments of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada
Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 4E3, Canada
These authors contributed equally to this work.
Author to whom correspondence should be addressed.
Received: 16 February 2013 / Revised: 20 March 2013 / Accepted: 22 March 2013 / Published: 10 April 2013
(This article belongs to the Special Issue Molecular Research in Urology)
View Full-Text   |   Download PDF [681 KB, uploaded 19 June 2014]   |  


MicroRNAs (miRNAs) have emerged as key regulators of numerous biological processes, and increasing evidence suggests that circulating miRNAs may be useful biomarkers of clinical disease. In this study, we sought to identify plasma miRNAs that differentiate patients with metastatic castration resistant prostate cancer (mCRPC) from those with localized prostate cancer (PCa). Pooled plasma samples from patients with localized PCa or mCRPC (25 per group) were assayed using the Exiqon miRNA qPCR panel, and the differential expression of selected candidates was validated using qRT-PCR. We identified 63 miRNAs upregulated in mCRPC versus localized PCa, while only four were downregulated. Pearson’s correlation analysis revealed two highly correlated groups: one consisting of miR-141, miR375 and miR-200c and the other including miR151-3p, miR423-3p, miR-126, miR152 and miR-21. A third group, containing miR-16 and miR-205, showed less correlation. One miRNA from each group (miR-141, miR151-3p and miR-16) was used for logistic regression analysis and proved to increase the sensitivity of the prostate-specific antigen (PSA) test alone. While no miRNA alone differentiated localized PCa and mCRPC, combinations had greater sensitivity and specificity. The expression of these 10 candidates was assayed for association with clinical parameters of disease progression through the cBio portal. Our results demonstrate that plasma levels of selected miRNAs are potential biomarkers to differentiate localized PCa and mCRPC.
Keywords: microRNA; prostate cancer; metastasis; PSA; castration resistant microRNA; prostate cancer; metastasis; PSA; castration resistant
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Supplementary materials

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Watahiki, A.; Macfarlane, R.J.; Gleave, M.E.; Crea, F.; Wang, Y.; Helgason, C.D.; Chi, K.N. Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer. Int. J. Mol. Sci. 2013, 14, 7757-7770.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top